Anti-TNF-α (Golimumab), Human IgG1 Antibody

• Data sheet: View or download

Golimumab is a human IgG1 kappa monoclonal antibody derived from HuMab transgenic mice immunized with human tumor necrosis factor alpha (TNF-α). This antibody targets and neutralizes soluble as well as transmembrane human TNF-α, which plays a key role in chronic inflammatory diseases such as Rheumatoid arthritis, inflammatory bowel disease, Crohn’s disease, Psoriatic arthritis, and ankylosing spondylitis. Golimumab was developed by Janssen Biotech and received FDA approval in 2009 for the treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and ankylosing spondylitis (AS). Additionally, in 2013, this antibody received approval for the treatment of ulcerative colitis. Golimumab is marketed under the trade name SIMPONI®